Company intelligence / Profile preview
ServareGMP
- Ownership
- Private
- Development stage
- Phase 1
Overview
ServareGMP is a non-profit biotechnology organization focused on developing and manufacturing ultra low-cost biologic medicines—primarily monoclonal antibodies—for infectious and neglected diseases. Its lead programs include ZAC3, an anti-cholera mAb in preclinical/early clinical development, and MBP1F5, an anti-Nipah virus mAb entering human trials in India and Bangladesh with CEPI funding. The company’s mission is to address unmet medical needs for the world’s most vulnerable populations by making advanced biologics accessible at radically reduced costs.[2][5][6]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodyBiologicProteinVaccineCell therapy
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on ServareGMP.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ServareGMP.